The Boston Scientific LOTUS(TM) Valve System Demonstrated Superior Efficacy to CoreValve(R) in Global REPRISE III Trial at One Year

PARIS and MARLBOROUGH, Mass., May 16, 2017 -- (Healthcare Sales & Marketing Network) -- Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris. Data... Devices, Interventional, Cardiology Boston Scientific, REPRISE III, LOTUS Valve, TAVI
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news